Table 3.
Main result; overall survival, distant metastasis free survival, loco-regional relapse free survival of the study
| Event | NAC-CCRTa, n (%) vs CCRT-ACb, n (%) | p-value |
|---|---|---|
| Hazard Ratio (95% confidence interval) | ||
| Overall survival | ||
| Dead | 21 (27%) vs 35 (19%) | 0.187 |
| Univariable analysis | 1.68 (0.98–2.90) | 0.059 |
| Multivariable analysisc | 0.83 (0.45–1.56) | 0.571 |
| Distant metastasis free survival | ||
| Distant metastasis | 13 (16%) vs 30 (16%) | 1.000 |
| Univariable analysis | 1.26 (0.66–2.42) | 0.483 |
| Multivariable analysisc | 0.79 (0.37–1.72) | 0.557 |
| Loco-regional relapse free survival | ||
| Loco-regional failure | 19 (24%) vs 18 (10%) | 0.003 |
| Univariable analysis | 2.88 (1.51–5.50) | 0.001 |
| Multivariable analysisc | 2.18 (0.98–4.87) | 0.057 |
aNAC-CCRT: neoadjuvant chemotherapy followed by concurrent chemo-radiotherapy
bCCRT-AC: concurrent chemo-radiotherapy followed by adjuvant chemotherapy
cAdjusted factors: gender, age, histology type, AJCC staging, complete of radiation treatment